A noteworthy observation from the present study is that the HepG2 and Huh-7 cells, which are highly TRAIL-resistant, increased in sensitivity to TRAIL following pretreatment with rocaglamide, supporting the possibility of investigating rocaglamide as an adjuvant to combination therapy for HCC patients. The gene discussed is TNFSF10; the disease is hepatocellular carcinoma.